1. Home
  2. |Insights
  3. |DEAL NOTE: Crowell & Moring Advises Marshall Wace on Series D Investment in InBrace

DEAL NOTE: Crowell & Moring Advises Marshall Wace on Series D Investment in InBrace

Firm News | 1 min read | 09.15.21

San Francisco—September 15, 2021: On September 8, 2021, InBrace, a dental company focused on teeth straightening, announced the closing of an oversubscribed $102 million Series D financing. Crowell & Moring represented co-lead investor Marshall Wace, a global alternative investment manager, in the transaction.  InBrace intends to use proceeds of the Series D financing to accelerate growth by expanding its sales force, launching new marketing initiatives, and driving further support and integration with new and existing orthodontic providers across the country.

The financing was co-led by Farallon Capital Management. Additional new investors included funds and accounts managed by BlackRock, Endeavour Vision, MVM Partners, RTW Investments, LP, and Soleus Capital Management, L.P. as well as funds affiliated with existing investors Vivo Capital, Novo Ventures, and venBio. The deal was led by Jon O’Connell with contributions from John Fuson, Anne Li, Steve Ryan, and Justin Lurie.

Insights

Firm News | 1 min read | 03.11.25

Crowell & Moring Represents Nuclear Energy Startup Atomic Alchemy in its Acquisition by Oklo

March 11, 2025: Oklo Inc. (NYSE: OKLO), an advanced nuclear technology company, announced on March 5, 2025 that it has closed the $25 million acquisition of Crowell client Atomic Alchemy Inc. (“Atomic Alchemy”), a leading innovator in radioisotope production. Oklo intends to use this strategic acquisition to establish a more reliable domestic supply chain for high-value radioisotopes critical to healthcare, research, and defense sectors and provides synergies to Oklo’s fuel recycling and nuclear energy businesses. Demand for radioisotopes is expected to increase significantly over the next decade, while global supply struggles to keep pace due to aging reactor infrastructure and a fragmented global supply chain, which at present is dominated by countries outside the United States. Atomic Alchemy intends to be a low-cost U.S. radioisotope producer that can provide a secure and domestic supply of radioisotopes to U.S. companies commercializing innovative radioisotope applications. With its proprietary VIPR® technology, Atomic Alchemy is building the first scalable production facility to provide a reliable, sustainable source of high-value radioisotopes. Using a vertically integrated model and fuel recycling, in partnership with Oklo, Atomic Alchemy is transforming isotope production to address global shortages, support critical applications, and strengthen national security. The core deal team included Samuel Holland Edwards, Jon O’Connell, Justin Lurie, and Ryan Flynn....